The Leukemia and Lymphoma Society (LLS) T-cells in Blood Cancer and COVID-19
Five hundred (500) patients participating in the LLS COVID-19 Registry, who have shown either no antibody or limited antibody response by way of the Spike Antibody test to one of the vaccinations authorized for emergency use (EUA) by FDA will participate in the LLS T-cells, Blood Cancer and COVID-19 Clinical Research Study. They will be followed for at least ten years (in the COVID-19 Registry). In addition, 500 patients with similar blood cancer diagnosis, also participating in the LLS COVID-19 Registry, who have shown full Spike antibody response to one of the vaccinations authorized for emergency use (EUA) by FDA will also be enrolled the LLS T-cells, Blood Cancer and COVID-19 Clinical Research Study for comparison (as a control arm) and will also be followed for at least 10 years (in the COVID-19 Registry).
Checked against the public recordLast updated Aug 17, 2022 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Larry Saltzman, MD
- Interventions being studied
- Diagnostic Test: ImmunoSEQ
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Select patients participating in the LLS COVID-19 Registry will be invited to enroll Exclusion Criteria: * People who have not participated in the LLS COVID-19 Registry
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Lymphoma and Leukemia SocietyRye Brook, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 17, 2022. Always confirm current availability with the study team.